Naramig (Naratriptan)

Naratriptan works by selectively activating serotonin 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and trigeminal nerve endings. This activation causes the vessels to constrict and blocks the release of inflammatory neuropeptides, thereby reducing the vascular and neural components that trigger migraine pain.

The exact dose of Naramig is determined by the prescribing healthcare professional. Typically, a single tablet is taken at the onset of a migraine attack, and a second dose may be considered after a specified interval if needed, but the prescriber sets the precise regimen based on individual patient factors.

Safety data for naratriptan in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made in consultation with a qualified healthcare provider.

To order Naramig, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Naramig (naratriptan) belongs to the triptan class, which is generally considered more selective for migraine relief than older ergot alkaloids. Compared with sumatriptan, another common triptan, naratriptan has a longer half‑life, offering a more extended period of symptom control, though individual response may vary.

Naramig tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and store them out of reach of children. Do not use the product after the expiration date printed on the label.

Naramig is taken orally as a whole tablet with a glass of water. It should be swallowed whole and not chewed or crushed. The tablet is usually taken at the first sign of a migraine attack, and patients should follow the dosing instructions provided by their prescriber.

The most serious risks include cardiovascular events such as coronary vasospasm, myocardial infarction, and severe hypertension, especially in patients with pre‑existing heart disease. Additionally, when combined with other serotonergic agents, there is a risk of serotonin syndrome, a potentially life‑threatening condition.

Naramig is contraindicated in individuals with known coronary artery disease, a history of stroke or transient ischemic attack, uncontrolled hypertension, severe hepatic impairment, or in patients who are currently taking MAO inhibitors, other triptans, or ergot derivatives.